DSM wins exclusive licence for innovative drug delivery technology
DSM Biomedical, a division of Dutch global life sciences and materials company, Royal DSM, has obtained an exclusive worldwide licence for a drug and biologic delivery system developed by MediVas, a San Diego-based biomedical company.
DSM Biomedical, a division of Dutch global life sciences and materials company, Royal DSM, has obtained an exclusive worldwide licence for a drug and biologic delivery system developed by MediVas, a San Diego-based biomedical company.
DSM Biomedical said the delivery system would open up a number of opportunities for next-generation drug delivery when integrated into its Trancerta platform.
MediVas' technology is based on a set of polymers exclusively licensed from Cornell University, which are biodegradable, biocompatible and bioabsorbable. Furthermore, they are non-inflammatory and allow greater control over the rate and duration of release of their therapeutic payload.
The technology can be used with a diverse group of drug candidates, from proteins, peptides and nucleic acids to small molecule drugs, thus expanding the possible application areas of the Trancerta platform.
DSM's licence applies to drug delivery systems aimed at treating ophthalmic, (cardio)vascular, musculoskeletal diseases and at providing general pain relief. MediVas will focus its r&d on nanoparticle-based therapies in oncology, immunology and on the delivery of nucleic acids.
"Through this deal we bring the first biodegradable polymer into DSM's biomedical portfolio, which significantly enhances our materials competences," said Steve Hartig, president of DSM Biomedical.
"The licence with DSM is an ideal strategic fit which will accelerate the efforts of MediVas to commercialise its novel biopolymer technology," added Kenneth Carpenter, chairman and ceo of MediVas.
